What to Do After a Relapse: 12 Questions to Ask Before Starting Treatment Again
A return to alcohol or drug use can feel like an emergency and a defeat at the same time. The most useful next move is not to repeat the previous plan automatically. It is to work out what failed, what changed, what remains dangerous, and what the next treatment plan must do differently.
First deal with immediate safety, overdose risk and withdrawal risk. Then review the 24–72 hours before the return to use, the treatment plan that was in place, medication adherence, cravings, mental health, environment and follow-up. The goal is to turn the episode into information that improves the next plan rather than simply restarting the same treatment.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an evidence-informed educational resource and is awaiting formal clinical approval. Until that review has taken place, it should not be represented as medically reviewed or authored by Dr Law.
View Dr Fergus Law’s professional profile
Do Not Ask Only “Why Did This Happen?” Ask “What Was Missing From the Plan?”
A return to substance use is emotionally charged. Families often focus on promises, motivation or honesty. Those questions can matter, but they are not enough to redesign treatment.
A more useful clinical question is: what combination of biological, psychological, environmental and treatment factors made substance use possible again?
Was the person still exposed to the same triggers? Were cravings treated? Was medication stopped or missed? Did counselling end too early? Was depression, trauma, pain or insomnia still active? Was there a gap between discharge and follow-up? Did the person return to the same home, contacts and routines?
The next treatment plan should answer those questions before another expensive or exhausting cycle begins.
Before the 12 Questions: Decide Whether This Is an Emergency
If the person is unresponsive, difficult to wake, breathing very slowly, not breathing normally, or has possible opioid exposure, call emergency services immediately. If naloxone is available and opioid overdose is suspected, administer it according to the product instructions and stay with the person until help arrives.
After a period of abstinence, opioid tolerance can fall. Returning to a previously familiar dose can therefore carry a greater overdose risk. CDC and NIDA both warn about increased risk when people return to opioids after loss of tolerance.
If a person has been drinking heavily or using sedatives regularly and then stops, do not assume home detox is safe. Severe withdrawal can require urgent medical assessment.
12 Questions to Ask Before Starting Treatment Again
1. What exactly was used, when, and in what amount?
Write down the substance, approximate amount, route of use, timing, whether more than one drug was involved, and whether alcohol, benzodiazepines or other sedatives were mixed with opioids. This helps identify overdose and withdrawal risks and prevents the next clinician from working from vague information.
2. What happened in the 24–72 hours before use?
Look for a sequence rather than a single trigger. Examples include poor sleep, conflict, payday, isolation, contact with a previous supplier, stopping medication, pain, shame after a mistake, missing counselling, travel or suddenly having unstructured time.
3. Were cravings present before the person used?
Ask when cravings started, how long they lasted, what the person tried, and whether anyone knew about them. A treatment plan that depends on the person quietly resisting escalating cravings may need a more active medical and behavioural strategy.
4. Was medication being taken exactly as planned?
For opioid use disorder, evidence-based medications include methadone, buprenorphine and naltrexone. For alcohol use disorder, approved options include naltrexone, acamprosate and disulfiram. If medication was stopped, delayed, missed or never offered, that is important information—not a side detail.
5. Was there a gap between detox or rehab and continuing care?
A common weak point is the handoff. Ask whether counselling, medication follow-up and recovery support were scheduled before discharge, and how many days passed before the first appointment. “Call us if you struggle” is not the same as a structured aftercare plan.
6. What problem was the substance solving?
Sometimes the person was trying to change a feeling or state: anxiety, depression, trauma symptoms, insomnia, loneliness, boredom, physical pain or emotional numbness. If the underlying problem remains untreated, abstinence may remove the substance without removing the reason it felt useful.
7. Did the environment change enough?
List people, places, devices, apps, money access, transport routes and times of day associated with use. Treatment can be excellent while the recovery environment remains high risk. The next plan may need practical changes, not only more counselling.
8. Was the level of care high enough—or unnecessarily high?
Some people need residential treatment or medically supervised withdrawal. Others may do well with outpatient care plus medication and structured follow-up. The right question is not “What is the most intensive treatment?” but “What level of care matches the person’s current medical, psychiatric and social risk?”
9. What was the first warning sign that nobody acted on?
Examples include missed appointments, changes in sleep, secrecy, romanticising previous use, contacting old friends, stopping medication, withdrawing from family, carrying unexplained cash or saying treatment is no longer necessary. Identify the earliest sign that could trigger action next time.
10. Is there a written overdose-prevention plan?
Where opioid exposure is possible, the plan should address naloxone availability, who knows how to use it, the danger of reduced tolerance after abstinence, and the risks of mixing opioids with alcohol or sedatives. Safety planning is not pessimism; it is risk management.
11. Does the family know how to help without becoming the police?
Families need a role they can actually sustain. Decide who will help with appointments, transport, medication reminders if appropriate, emergency planning and practical structure—and where boundaries are needed. Constant interrogation can create conflict without reducing clinical risk.
12. What will be materially different this time?
This is the most important question. Before committing to another program, write down three to five changes that will exist in the new plan. If the answer is only “try harder,” “stay longer,” or “be more motivated,” the treatment design may not have changed enough.
Turn the Answers Into a Treatment-Reset Map
| What you discover | What it may mean for the next plan |
|---|---|
| Strong cravings appeared repeatedly | Discuss medication options, adherence strategy and a clear craving-response plan with a qualified clinician. |
| Medication was missed or stopped | Explore why adherence failed and whether a different formulation, monitoring approach or treatment pathway is appropriate. |
| Use followed depression, trauma symptoms or insomnia | Add or strengthen mental-health assessment and treatment rather than treating substance use in isolation. |
| Return to use happened immediately after discharge | Strengthen the transition plan so follow-up, medication and support are active before the person returns home. |
| The same people or places were involved | Make environmental changes specific, measurable and immediate. |
| The person was alone and nobody knew risk was increasing | Create earlier check-ins and an escalation plan for cravings, missed appointments or behavioural warning signs. |
| Opioid use returned after abstinence | Review overdose risk, naloxone access and evidence-based OUD medication options urgently. |
A Simple 7-Day Reset Plan
- Day 1: address emergency, overdose and withdrawal risk; secure naloxone where opioid exposure is possible.
- Day 1–2: document what was used and the 72-hour lead-up without turning the conversation into an interrogation.
- Day 2–3: contact a qualified treatment professional and review whether detox, medication changes or a different level of care is needed.
- Day 3–4: identify the three biggest treatment gaps from the previous attempt.
- Day 4–5: change the environment—contacts, access to substances, money, transport, isolation and high-risk routines.
- Day 5–6: schedule continuing care before any discharge or transition.
- Day 7: write the relapse-prevention plan in one page: warning signs, who to call, medication plan, appointments, emergency steps and what happens if use returns.
Keep the plan short enough that the person and family can use it under stress.
Do Not Let Medication Be an Afterthought
SAMHSA identifies methadone, buprenorphine and naltrexone as common FDA-approved medications for opioid use disorder. For alcohol use disorder, NIAAA lists naltrexone, acamprosate and disulfiram as FDA-approved options. Medication is not right for every person, but a treatment program should be able to explain whether it is relevant and why.
Was medication offered?
If not, ask why. “We do not use medication” is not the same as an individualized clinical reason.
Did adherence fail?
If daily medication was repeatedly missed, the next plan should address adherence directly rather than assuming it will improve on its own.
Was the timing safe?
Naltrexone for opioid use disorder requires an appropriate opioid-free period to avoid precipitated withdrawal. Timing must be medically assessed.
What happens after medication starts?
Medication should sit inside a broader plan that may include counselling, mental-health care, environmental changes and follow-up.
For more detail, read Medication for Opioid Relapse Prevention: What Are the Options?
A Good Consultation Should Tell You What Needs to Change—Not Simply Sell You Another Program
If someone has completed detox or rehab and returned to substance use, a second opinion can be useful when the family is about to spend more money, travel for treatment or repeat a program that looks very similar to the last one.
A focused consultation should help clarify:
- whether immediate detox or medical stabilization is required;
- which part of the previous plan appears to have broken down;
- whether medication for opioid or alcohol use disorder should be discussed;
- whether cravings, adherence, mental health, pain, sleep or environment need a different strategy;
- what continuing care should already be booked before discharge;
- whether DeBinge’s Nassau-based treatment model is relevant—or whether another route makes more sense.
Before You Repeat the Same Treatment, Find Out What Should Be Different
DeBinge offers a confidential consultation for people and families considering next steps after a return to substance use. The purpose is to review the treatment history, current risks, previous relapse pattern and appropriate options. Suitability for any DeBinge treatment is assessed individually; no treatment or outcome can be guaranteed.
If someone may be experiencing an overdose, severe withdrawal, suicidal crisis or another medical emergency, use local emergency services rather than waiting for a routine consultation.
Questions Families Often Ask After a Return to Use
Does a relapse mean treatment failed?
Not necessarily. It means the current recovery plan needs reassessment. The useful question is what changed before the return to use and what the next plan needs to address differently.
Should someone go straight back to rehab?
Sometimes residential treatment is appropriate, but the right level of care depends on medical risk, withdrawal risk, psychiatric needs, substance used, home environment and available support. A qualified clinician should assess those factors.
Should medication be considered after relapse?
For opioid and alcohol use disorders, evidence-based medications may be appropriate for some patients. Selection and timing require individualized medical assessment.
Why is opioid relapse especially dangerous after abstinence?
Opioid tolerance can decrease during abstinence. Returning to a dose previously tolerated can therefore carry greater overdose risk. Naloxone and evidence-based OUD treatment should be discussed where opioid exposure is possible.
What should a family bring to a consultation?
A simple timeline of recent use, previous detox or rehab episodes, current medications, known mental-health diagnoses, major triggers, previous treatment records if available, and the 12-question review above.
Continue the Treatment-Reset Process
Evidence and Further Reading
SAMHSA — Treatment Options for Substance Use Disorder
Overview of evidence-based treatment and medications for opioid and alcohol use disorders.
SAMHSA — Naltrexone
Clinical information on naltrexone, opioid-free preparation and reduced opioid tolerance after discontinuation or abstinence.
CDC — Naloxone and Opioid Overdose Prevention
Practical guidance on recognizing suspected opioid overdose, using naloxone and reducing overdose risk.
NIAAA — Treatment for Alcohol Problems
Evidence-based alcohol treatment options, including behavioural care and FDA-approved medications.
Last updated: September 2026. This page provides general educational information and does not establish a doctor-patient relationship.